These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 30850565)

  • 1. Nivolumab-induced hypophysitis leading to hypopituitarism and secondary empty sella syndrome in a patient with non-small cell lung cancer.
    Chang J; Tran J; Kamel D; Basu A
    BMJ Case Rep; 2019 Mar; 12(3):. PubMed ID: 30850565
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nivolumab-induced Hypophysitis, Secondary Adrenal Insufficiency and Destructive Thyroiditis in a Patient with Lung Adenocarcinoma.
    Mishima Y; Fukaishi T; Inase N; Isogai S
    Intern Med; 2019 Mar; 58(5):693-697. PubMed ID: 30449786
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nivolumab-induced hypophysitis causing secondary adrenal insufficiency after transient ACTH elevation.
    Sekizaki T; Kameda H; Oba C; Yong Cho K; Nakamura A; Miyoshi H; Osawa T; Shinohara N; Atsumi T
    Endocr J; 2019 Oct; 66(10):937-941. PubMed ID: 31217401
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nivolumab-induced hypothyroidism followed by isolated ACTH deficiency.
    Martins Machado C; Almeida Santos L; Barroso A; Oliveira MJ
    BMJ Case Rep; 2019 Aug; 12(8):. PubMed ID: 31466960
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Nivolumab induced hypophysitis in a patient with recurrent non-small cell lung cancer.
    Kajal S; Gupta P; Ahmed A; Gupta A
    Drug Discov Ther; 2021 Sep; 15(4):218-221. PubMed ID: 34456195
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Isolated adrenocorticotropic hormone deficiency and thyroiditis associated with nivolumab therapy in a patient with advanced lung adenocarcinoma: a case report and review of the literature.
    Ohara N; Kobayashi M; Ohashi K; Ito R; Ikeda Y; Kawaguchi G; Yoneoka Y; Hasegawa G; Takada T
    J Med Case Rep; 2019 Mar; 13(1):88. PubMed ID: 30909965
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Late-onset hypophysitis after discontinuation of nivolumab treatment for advanced skin melanoma: a case report.
    Antoniou S; Bazazo G; Röckl L; Papadakis M; Berg C
    BMC Endocr Disord; 2021 Sep; 21(1):191. PubMed ID: 34544399
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hypophysitis: A rare but noteworthy immune-related adverse event secondary to camrelizumab therapy.
    Han X; Meng M; Zhang T; Wang J; Huang G; Ni Y; Li W; Dai J; Yang X; Ye X
    J Cancer Res Ther; 2022 Sep; 18(5):1440-1443. PubMed ID: 36204895
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immune Checkpoint Inhibitor-Associated Central Adrenal Insufficiency.
    Mishra T; He G; Sreeram K; Rauf M; Subahi A; Hazem M
    Am J Ther; 2019; 26(5):e626-e627. PubMed ID: 30277909
    [No Abstract]   [Full Text] [Related]  

  • 10. Sequential occurrence of primary and secondary hypothyroidism during treatment with nivolumab: pitfalls in immuno-oncological therapy and endocrinological diagnostic procedures.
    Ansorge C; Seufert J; Meiss F; von Bubnoff D
    J Dtsch Dermatol Ges; 2018 Dec; 16(12):1483-1485. PubMed ID: 30411844
    [No Abstract]   [Full Text] [Related]  

  • 11. Isolated Adrenocorticotropin Deficiency due to Nivolumab-induced Hypophysitis in a Patient with Advanced Lung Adenocarcinoma: A Case Report and Literature Review.
    Ohara N; Ohashi K; Fujisaki T; Oda C; Ikeda Y; Yoneoka Y; Hashimoto T; Hasegawa G; Suzuki K; Takada T
    Intern Med; 2018 Feb; 57(4):527-535. PubMed ID: 29151505
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Corticotropic insufficiency in a monocentric prospective cohort of patients with lung cancer treated with nivolumab: Prevalence and etiology.
    Ducloux R; Tavernier JY; Wojewoda P; Toullet F; Romanet S; Averous V
    Ann Endocrinol (Paris); 2021 Feb; 82(1):8-14. PubMed ID: 33290748
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Unusual presentation of hypophysitis preceding an empty sella in a 75-year-old woman.
    Klein J; Fehm HL
    Neuro Endocrinol Lett; 2005 Dec; 26(6):757-8. PubMed ID: 16380671
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Nivolumab-induced adrenalitis.
    Iqbal I; Khan MAA; Ullah W; Nabwani D
    BMJ Case Rep; 2019 Dec; 12(11):. PubMed ID: 31791986
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Recovery from secondary adrenal insufficiency in a patient with immune checkpoint inhibitor therapy induced hypophysitis.
    Thapi S; Leiter A; Galsky M; Gallagher EJ
    J Immunother Cancer; 2019 Sep; 7(1):248. PubMed ID: 31511065
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Isolated Adrenocorticotropic Hormone Deficiency Caused by Nivolumab in a Patient with Metastatic Lung Cancer.
    Takaya K; Sonoda M; Fuchigami A; Hiyoshi T
    Intern Med; 2017 Sep; 56(18):2463-2469. PubMed ID: 28824067
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunotherapy-induced autoimmune hypophysitis.
    Valecha G; Pant M; Ibrahim U; Atallah JP
    J Oncol Pharm Pract; 2019 Jan; 25(1):217-220. PubMed ID: 28825378
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Muscle weakness as first manifestation of panhypopituitarism secondary to empty sella syndrome].
    Paz Flores C; Rosales Carballa J; Blanco Loberías J
    An Med Interna; 2008 Jun; 25(6):309-11. PubMed ID: 19295984
    [No Abstract]   [Full Text] [Related]  

  • 19. Case of hypophysitis caused by nivolumab.
    Ishikawa M; Oashi K
    J Dermatol; 2017 Jan; 44(1):109-110. PubMed ID: 27178147
    [No Abstract]   [Full Text] [Related]  

  • 20. Checkpoint Inhibitor-Associated Hypophysitis.
    Chang LS; Yialamas MA
    J Gen Intern Med; 2018 Jan; 33(1):125-127. PubMed ID: 28770379
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.